Vaxart Inc (NASDAQ:VXRT) Expected to Post Quarterly Sales of $440,000.00

Brokerages predict that Vaxart Inc (NASDAQ:VXRT) will report sales of $440,000.00 for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Vaxart’s earnings. The highest sales estimate is $800,000.00 and the lowest is $90,000.00. Vaxart posted sales of $280,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 57.1%. The company is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Vaxart will report full-year sales of $6.78 million for the current fiscal year, with estimates ranging from $5.67 million to $7.90 million. For the next financial year, analysts anticipate that the business will report sales of $11.70 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Vaxart.

Vaxart (NASDAQ:VXRT) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.11. Vaxart had a negative return on equity of 131.05% and a negative net margin of 244.38%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $1.10 million.

Several research analysts have weighed in on VXRT shares. HC Wainwright set a $2.00 target price on Vaxart and gave the company a “buy” rating in a research note on Wednesday, August 21st. ValuEngine downgraded Vaxart from a “buy” rating to a “hold” rating in a research note on Monday, September 30th. Zacks Investment Research upgraded Vaxart from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Friday, August 30th. Finally, Brookline Capital Management initiated coverage on Vaxart in a report on Thursday, August 15th. They issued a “buy” rating and a $6.00 price target for the company.

Shares of VXRT stock traded up $0.01 during midday trading on Monday, hitting $0.38. The company had a trading volume of 140,729 shares, compared to its average volume of 583,242. The company’s 50 day simple moving average is $0.52 and its 200 day simple moving average is $0.73. Vaxart has a 52-week low of $0.25 and a 52-week high of $5.00. The stock has a market cap of $5.99 million, a price-to-earnings ratio of -0.14 and a beta of 0.57. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.29.

In other news, insider Wouter Latour acquired 166,667 shares of Vaxart stock in a transaction that occurred on Monday, September 30th. The stock was purchased at an average cost of $0.30 per share, with a total value of $50,000.10. Also, major shareholder Armistice Capital Master Fund acquired 7,333,333 shares of Vaxart stock in a transaction that occurred on Monday, September 30th. The shares were purchased at an average cost of $0.29 per share, with a total value of $2,126,666.57. Insiders bought a total of 8,520,000 shares of company stock valued at $2,539,907 over the last three months. Insiders own 7.30% of the company’s stock.

An institutional investor recently raised its position in Vaxart stock. Renaissance Technologies LLC increased its position in shares of Vaxart Inc (NASDAQ:VXRT) by 120.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 739,653 shares of the biotechnology company’s stock after buying an additional 404,883 shares during the quarter. Renaissance Technologies LLC owned about 4.69% of Vaxart worth $496,000 as of its most recent SEC filing. 12.51% of the stock is currently owned by institutional investors and hedge funds.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.

Read More: Limitations of analyzing profit margin

Get a free copy of the Zacks research report on Vaxart (VXRT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with's FREE daily email newsletter.